Grant of patent in Australia

RNS Number : 0927C

Eden Research plc

26 April 2012

 



GB0001646941/GBP/PLUS-exn

EDEN RESEARCH PLC

("Eden" or "Company")

Grant of patent in Australia

Eden Research plc, the agrochemical and encapsulation development company, announces that it has received a Grant of Patent from the Commonwealth of Australia Patent Office for its platform encapsulation technology.

The patent covers the Company's core technology, specifically "compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them."

The Patent, number 2005245190, expires in 2025.

Clive Newitt, Managing Director of Eden said, "This is yet another geography where Eden's proprietary encapsulation technology now has patent protection. Australia is a key region for the use of agrochemicals, particularly with their established wine making industry, where we believe our unique, environmentally friendly solutions to problems like Botrytis (a fungus that affects grapes) will generate strong demand."

The Directors of Eden are responsible for the contents of this announcement.

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
Zeus Capital Limited	Tel: [phone]
Ross Andrews, Andrew Jones, Brian Stockbridge
Walbrook PR Ltd	Tel: [phone]
Paul McManus (Media Relations)	Mob: [phone] or [e-mail]
Paul Cornelius (Investor Relations)	Mob: [phone] or [e-mail]

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCKELFLLZFZBBB